BridgeBio Pharma recently reported a strong and accelerating launch of its heart drug Attruby, with rapid growth in unique patient prescriptions and prescribers, supported by compelling clinical ...
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks 2nd on this list. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a relatively ...
Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
Pfizer’s recent positive data for atirmociclib, tilrekimig, Padcev, and the Lyme disease vaccine candidate highlight pipeline ...
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...
Adds Pfizer statement. BridgeBio (BBIO) fell 1.3% after originally gaining 11% as a court filing disclosed a settlement in a ...
CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1. PALO ALTO, ...
The firm expects Attruby sales in ATTR-CM to exceed consensus estimates of $173 million when the company reports first-quarter earnings on April 30. This aligns with an InvestingPro Tip highlighting ...
Hosted on MSN
Pfizer settles to delay Vyndamax generics until 2031
Pfizer has reached settlements with three generic drugmakers, pushing back U.S. market entry of Vyndamax copies until mid-2031, pending other litigation. The move preserves billions in annual revenue ...
Barclays has reiterated its Overweight rating on the company, with expectations of first-quarter U.S. Attruby revenue reaching $175 million, surpassing the consensus estimate of $169 million. Total ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results